鍒╀紣娌欑彮锛堣嫳璇細Rivaroxaban锛夛紝浠arelto绛夊搧鐗岄攢鍞紝鏄竴绉嶇敤浜庢不鐤楀拰棰勯槻琛€鏍撶殑鎶楀嚌鑽墿锛堣娑茬█閲婂墏锛夈€傚叿浣撹€岃█锛屽畠鐢ㄤ簬娌荤枟娣遍潤鑴夎鏍撳舰鎴愬拰鑲烘爴濉烇紝骞堕闃插績鎴块ⅳ鍔ㄥ拰楂嬪叧鑺傛垨鑶濆叧鑺傛墜鏈悗鐨勮鏍撱€傚畠鏄彛鏈嶇殑銆?/p>
甯歌鐨勫壇浣滅敤鍖呮嫭鍑鸿銆傚叾浠栦弗閲嶇殑鍓綔鐢ㄥ彲鑳藉寘鎷剨楂撶‖鑶滃琛€鑲垮拰杩囨晱鎬т紤鍏嬨€傜洰鍓嶅皻涓嶆竻妤氬湪鎬€瀛曞拰鍝轰钩鏈熼棿浣跨敤鏄惁瀹夊叏銆備笌鍗庢硶鏋楃浉姣旓紝瀹冧笌鍏朵粬鑽墿鐨勭浉浜掍綔鐢ㄨ緝灏戙€傚畠閫氳繃闃绘柇鍑濊铔嬬櫧鍑濊鍥犲瓙Xa鐨勬椿鎬ц捣浣滅敤銆?/p>
鍒╀紣娌欑彮浜?007骞磋幏寰椾笓鍒╋紝骞朵簬2011骞村湪缇庡浗鑾锋壒鐢ㄤ簬鍖荤枟鐢ㄩ€斻€傚湪缇庡浗锛岀洿鍒?024骞村畠鎵嶈兘浣滀负浠垮埗鑽娇鐢ㄣ€傚畠琚垪鍏ヤ笘鐣屽崼鐢熺粍缁囧熀鏈嵂鐗╂爣鍑嗘竻鍗曢噷銆傚湪2019骞达紝瀹冩槸缇庡浗绗?1绉嶆渶甯哥敤鐨勫鏂硅嵂锛屾湁瓒呰繃800涓囧紶澶勬柟銆?/p>
鍘嗗彶
鍒╀紣娌欑彮鏈€鍒濈敱鎷滆€冲叕鍙稿紑鍙戠殑銆傚湪缇庡浗锛屽畠鐢辨潹妫埗鑽紙寮虹敓鍏徃鐨勪竴閮ㄥ垎锛夐攢鍞€傚畠鏄涓€涓彛鏈嶇殑鐩存帴鍑濊鍥犲瓙Xa鎶戝埗鍓傘€?/p>
鍖荤敤
鍦ㄩ潪鐡ｈ啘鎬у績鎴块ⅳ鍔ㄦ偅鑰呬腑锛屽畠鍦ㄩ闃茬己琛€鎬т腑椋庡拰鏍撳浜嬩欢鏂归潰浼间箮涓庡崕娉曟灄涓€鏍锋湁鏁堛€備笌鍗庢硶鏋楃浉姣旓紝鍒╀紣娌欑彮涓庝弗閲嶅拰鑷村懡鍑鸿浜嬩欢鐨勫彂鐢熺巼杈冧綆鐩稿叧锛屽敖绠″埄浼愭矙鐝笌娑堝寲閬撳嚭琛€鐜囪緝楂樻湁鍏炽€?/p>
2012骞?鏈堬紝鑻卞浗鍥藉鍋ュ悍涓庝复搴婂崜瓒婄爺绌舵墍鎺ㄨ崘鍒╀紣娌欑彮棰勯槻鍜屾不鐤楅潤鑴夎鏍撱€?/p>
绂佸繉
鐢变簬涓庢帶鍒跺嚭琛€鐩稿叧鐨勫洶闅撅紝鍒╀紣娌欑彮搴斿湪鎵嬫湳鍓嶈嚦灏?4灏忔椂鍋滅敤锛岀劧鍚庡湪纭畾鍏呭垎姝㈣鍚庣珛鍗抽噸鏂板紑濮嬨€?/p>
鍓傞噺寤鸿涓嶅缓璁皢鍒╀紣娌欑彮涓庡凡鐭ヤ负寮鸿仈鍚圕YP3A4/P-绯栬泲鐧芥姂鍒跺墏鐨勮嵂鐗╁悎鐢紝鍥犱负杩欎細瀵艰嚧鍒╀紣娌欑彮鐨勮娴嗘祿搴︽樉鐫€鍗囬珮銆?/p>
涓嶅埄褰卞搷
鏈€涓ラ噸鐨勪笉鑹弽搴旀槸鍑鸿锛屽寘鎷弗閲嶇殑鍐呭嚭琛€銆備笌鍗庢硶鏋楃浉姣旓紝鍒╀紣娌欑彮鐨勪弗閲嶅拰鑷村懡鍑鸿浜嬩欢鍙戠敓鐜囪緝浣庯紝浣嗘秷鍖栭亾鍑鸿鍙戠敓鐜囪緝楂樸€?/p>
鎴2015骞达紝涓婂競鍚庤瘎浼版樉绀鸿倽姣掓€э紝闇€瑕佽繘涓€姝ョ爺绌舵潵閲忓寲杩欑椋庨櫓銆傚湪2015骞达紝鍦‵DA涓嶈壇浜嬩欢鎶ュ憡绯荤粺锛圓ERS锛夌殑瀹氭湡鐩戞祴鑽墿涓紝鍒╀紣娌欑彮琚姤鍛婄殑涓ラ噸浼ゅ鐥呬緥鏁版渶澶氥€?/p>
閫嗚浆鍓?/h3>
2014骞?0鏈堬紝PortolaPharmaceuticals瀹屾垚浜哸ndexanetalfa浣滀负鍑濊鍥犲瓙Xa鎶戝埗鍓傜殑瑙ｆ瘨鍓備笖鍓綔鐢ㄥ皯鐨処鏈熷拰II鏈熶复搴婅瘯楠岋紝骞跺惎鍔ㄤ簡涓夋湡璇曢獙銆侫ndexanetalfa浜?018骞?鏈堣幏寰楃編鍥介鍝佸拰鑽墿绠＄悊灞€鐨勬壒鍑嗭紝鍟嗗搧鍚嶄负Andexxa銆?/p>
浣滅敤鏈哄埗
鍒╀紣娌欑彮鎶戝埗鍑濊閰跺師閰跺鍚堢墿涓父绂诲拰缁撳悎鐨勫嚌琛€鍥犲瓙Xa銆傚畠鏄竴绉嶉€夋嫨鎬х洿鎺ュ嚌琛€鍥犲瓙Xa鎶戝埗鍓傦紝璧锋晥鏃堕棿涓?.5鑷?灏忔椂銆傚嚌琛€鍥犲瓙Xa鐨勬姂鍒朵細涓柇鍑濊绾ц仈鐨勫唴鍦ㄥ拰澶栧湪閫斿緞锛屼粠鑰屾姂鍒跺嚌琛€閰剁殑褰㈡垚鍜岃鏍撶殑鍙戝睍銆傚埄浼愭矙鐝笉鎶戝埗鍑濊閰讹紙婵€娲荤殑鍑濊鍥犲瓙II锛夛紝骞朵笖宸茶瘉鏄庡琛€灏忔澘娌℃湁褰卞搷銆傚畠鍏佽鍙娴嬬殑鎶楀嚌鍜屽墏閲忚皟鏁翠互鍙婂父瑙勫嚌琛€鐩戞祴锛涗笉闇€瑕侀ギ椋熼檺鍒躲€?/p>
鏅€氳倽绱犮€佷綆鍒嗗瓙閲忚倽绱犲拰纾鸿揪鑲濈礌涔熼€氳繃涓庡惊鐜姉鍑濊閰剁粨鍚堣€岄棿鎺ユ姂鍒跺嚌琛€鍥犲瓙Xa鐨勬椿鎬у苟涓斿繀椤婚€氳繃娉ㄥ皠锛岃€屽彛鏈嶆椿鎬у崕娉曟灄銆佽嫰涓欓璞嗙礌鍜岄唻纭濋璞嗙礌鏄淮鐢熺礌K鎷姉鍓傦紝鍙檷浣庤澶氬嚌琛€鍥犲瓙锛屽寘鎷嚌琛€鍥犲瓙Xa銆?/p>
鍒╀紣娌欑彮鍦ㄥ箍娉涚殑鎮ｈ€咃紙骞撮緞銆佹€у埆銆佷綋閲嶃€佺鏃忥級涓叿鏈夊彲棰勬祴鐨勮嵂鐗╀唬璋㈠姩鍔涘锛屽苟涓斿湪鍏€嶅墏閲忚寖鍥达紙5-40mg锛夊唴鍏锋湁骞冲潶鐨勫墏閲忓弽搴斻€傚彛鏈嶇敓鐗╁埄鐢ㄥ害鏄墏閲忎緷璧栨€х殑銆?0mg浠ヤ笅鐨勫埄浼愭矙鐝墏閲忓彲浠ュ湪鏈夋垨娌℃湁椋熺墿鐨勬儏鍐典笅鏈嶇敤锛屽洜涓哄畠鏄剧ず鍑洪珮鐢熺墿鍒╃敤搴︼紝鑰屼笌鏄惁椋熺敤椋熺墿鏃犲叧銆傚鏋滀互15mg鎴?0mg鍙ｆ湇鍓傞噺缁欎簣鍒╀紣娌欑彮锛屽垯闇€瑕佷笌椋熺墿涓€璧锋湇鐢ㄤ互甯姪鑽墿鍚告敹骞惰揪鍒伴€傚綋鐨勭敓鐗╁埄鐢ㄥ害锛堚墺80%锛夈€?/p>
鍖栧
鍒╀紣娌欑彮涓庢姉鐢熺礌鍒╁鍞戣兒鏈夌潃鎯婁汉鐨勭粨鏋勭浉浼兼€э細涓ょ鑽墿鍏锋湁鐩稿悓鐨勷囧攽鐑烽叜琛嶇敓鏍稿績缁撴瀯銆傚洜姝わ紝鍒╀紣娌欑彮宸茶鐮旂┒浜嗕换浣曞彲鑳界殑鎶楄弻浣滅敤鍜岀嚎绮掍綋姣掓€х殑鍙兘鎬э紝绾跨矑浣撴瘨鎬ф槸闀挎湡浣跨敤鍒╁鍞戣兒鐨勫凡鐭ュ苟鍙戠棁銆傜爺绌跺彂鐜帮紝鍒╀紣娌欑彮鍙婂叾浠ｈ阿鐗╅兘瀵归潻鍏版皬闃虫€ц弻娌℃湁浠讳綍鎶楃敓绱犱綔鐢ㄣ€傝嚦浜庣嚎绮掍綋姣掓€э紝2008骞翠箣鍓嶅彂琛ㄧ殑浣撳鐮旂┒鍙戠幇椋庨櫓寰堜綆銆?/p>
绀句細涓庢枃鍖?/h2>缁忔祹鎬?/h3>
鏍规嵁缇庡浗鏈€澶х殑鑽埧绂忓埄绠＄悊鍏徃蹇嵎鑽柟鐨勬暟鎹紝浣跨敤鍒╀紣娌欑彮鑰岄潪鍗庢硶鏋楃殑鎴愭湰瑕侀珮鍑?0鍊嶃€傛埅鑷?016骞达紝鎷滆€冲叕鍙稿０绉拌鑽墿宸插湪130涓浗瀹惰幏寰楄鍙紝瓒呰繃2300涓囨偅鑰呮帴鍙椾簡娌荤枟銆?/p>
鍚屾剰璁稿彲
鍦?008骞?鏈堬紝鍔犳嬁澶у崼鐢熼儴鎺堜簣鍒╀紣娌欑彮鐨勪笂甯傝鍙紝鐢ㄤ簬棰勯槻鎺ュ彈閫夋嫨鎬у叏楂嬪叧鑺傜疆鎹㈡湳鎴栧叏鑶濆叧鑺傜疆鎹㈡湳鎮ｈ€呯殑闈欒剦琛€鏍撱€?/p>
鍚屾湀锛屾鐩熷鍛樹細涔熸巿浜堝埄浼愭矙鐝殑涓婂競璁稿彲锛岀敤浜庨闃叉帴鍙楁嫨鏈熼珛鍏宠妭鍜岃啙鍏宠妭缃崲鏈殑鎴愪汉闈欒剦琛€鏍撴爴濉炵棁銆?/p>
鍦?011骞?鏈?鏃ワ紝缇庡浗椋熷搧鍜岃嵂鐗╃鐞嗗眬鎵瑰噯鍒╀紣娌欑彮鍦ㄦ帴鍙楅珛鍏宠妭鍜岃啙鍏宠妭缃崲鎵嬫湳鐨勬垚浜轰腑棰勯槻鍙兘瀵艰嚧鑲烘爴濉炵殑娣遍潤鑴夎鏍撳舰鎴愩€?/p>
鍦?011骞?1鏈?鏃ワ紝缇庡浗FDA鎵瑰噯鍒╀紣娌欑彮鐢ㄤ簬闈炵摚鑶滃績鎴块ⅳ鍔ㄦ偅鑰呯殑鍗掍腑棰勯槻銆?/p>
鍚堟硶涓惧姩
鍦?019骞?鏈?5鏃ワ紝鍦ㄧ編鍥芥湁25,000澶氳捣鍏充簬鍒╀紣娌欑彮鐨勮瘔璁间互7.75浜跨編鍏冨拰瑙ｏ紝浠ユ敮浠樼粰鍙楀奖鍝嶇殑浜恒€傚師鍛婃寚璐ｅ埗鑽晢娌℃湁璀﹀憡鍑鸿椋庨櫓锛屽０绉板鏋滃悜鍖荤敓鍜屾偅鑰呮彁渚涜冻澶熺殑淇℃伅锛屼粬浠殑浼ゅ鏄彲浠ラ伩鍏嶇殑銆?/p>
鐮旂┒
鏉滃厠澶у鍖诲闄㈢殑鐮旂┒浜哄憳琚寚鎺ч殣鐬掔敤浜庤瘎浼板埄浼愭矙鐝殑涓村簥鏁版嵁銆傛潨鍏嬪ぇ瀛﹀湪涓€椤瑰悕涓篟OCKETAF璇曢獙鐨勪复搴婅瘯楠屼腑娴嬭瘯浜嗗埄浼愭矙鐝€傝涓村簥璇曢獙浜?011骞村彂琛ㄥ湪銆婃柊鑻辨牸鍏板尰瀛︽潅蹇椼€嬩笂骞剁敱鏃朵换FDA涓撳憳缃椾集鐗孤峰崱鍒╁か棰嗗锛屽彂鐜板埄浼愭矙鐝湪闄嶄綆鎴块ⅳ鎮ｈ€呯己琛€鎬у崚涓殑鍙兘鎬ф柟闈㈡瘮鍗庢硶鏋楁洿鏈夋晥銆傝鐮旂┒鐨勬湁鏁堟€у湪2014骞村彈鍒拌川鐤戯紝褰撴椂鍒惰嵂璧炲姪鍟嗘嫓鑰冲叕鍙稿拰寮虹敓鍏徃閫忛湶鎵€浣跨敤鐨処NRatio琛€娑茬洃娴嬭澶囪繍琛屼笉姝ｅ父銆傛潨鍏嬪洟闃熼殢鍚庡湪2016骞?鏈堝彂琛ㄧ殑涓€椤瑰垎鏋愬彂鐜帮紝杩欏浜庤瘯楠岀殑鐤楁晥鍜屽畨鍏ㄦ€ф病鏈夋樉鐫€褰卞搷銆?/p>
涓村簥璇曢獙涓皯鏁版棌瑁旂殑浠ｈ〃鎬т笉瓒冲凡缁忚缁忔敞鎰忓埌銆備笌鍗庢硶鏋楃浉姣旓紝涓嶅悓绉嶆棌浜氱粍鐨勭枟鏁堝拰瀹夊叏鎬х浉浼笺€?/p>
鍙傝€冩枃鐚?/h2>- ^RivaroxabanUseDuringPregnancy.Drugs.com.[March3,2019].锛堝師濮嬪唴瀹瑰瓨妗ｄ簬2019-03-27锛?
- ^Xarelto-rivaroxabantablet,filmcoatedXarelto-rivaroxabantablet,filmcoatedXarelto-rivaroxabankit.DailyMed.[November13,2020].锛堝師濮嬪唴瀹瑰瓨妗ｄ簬2021-04-19锛?
- ^XareltoEPAR.EuropeanMedicinesAgency(EMA).[November13,2020].锛堝師濮嬪唴瀹瑰瓨妗ｄ簬2023-01-27锛?
- ^Xarelto:SummaryofProductCharacteristics.BayerScheringPharmaAG.2008[February11,2009].锛堝師濮嬪唴瀹瑰瓨妗ｄ簬2010-07-27锛?
- ^AbdulsattarY,BhambriR,NogidA.Rivaroxaban(xarelto)forthepreventionofthromboembolicdisease:aninsidelookattheoraldirectfactorxainhibitor.P&T.May2009,34(5):238鈥?4..PMID聽19561868.
- ^RivaroxabanMonographforProfessionals.Drugs.com.AmericanSocietyofHealth-SystemPharmacists.[March3,2019].锛堝師濮嬪唴瀹瑰瓨妗ｄ簬2019-03-27锛?
- ^KiserK.OralAnticoagulationTherapy:CasesandClinicalCorrelation.Springer.2017:11.ISBN9783319546438.
- ^GenericXareltoAvailability.Drugs.com.[May9,2017].锛堝師濮嬪唴瀹瑰瓨妗ｄ簬2018-06-16锛?
- ^OrangeBook:ApprovedDrugProductswithTherapeuticEquivalenceEvaluations.www.accessdata.fda.gov.[April24,2019].锛堝師濮嬪唴瀹瑰瓨妗ｄ簬2020-09-13锛?
- ^Bayer,J&JWinRulingThatUpholdsPatentforXareltoDrug.April22,2019[April24,2019].锛堝師濮嬪唴瀹瑰瓨妗ｄ簬2019-08-01锛?
- ^WorldHealthOrganization.WorldHealthOrganizationmodellistofessentialmedicines:22ndlist(2021).Geneva:WorldHealthOrganization.2021..WHO/MHP/HPS/EML/2021.02.
- ^TheTop300of2019.ClinCalc.[October16,2021].锛堝師濮嬪唴瀹瑰瓨妗ｄ簬2020-03-18锛?
- ^Rivaroxaban-DrugUsageStatistics.ClinCalc.[October16,2021].锛堝師濮嬪唴瀹瑰瓨妗ｄ簬2020-07-08锛?
- ^XareltoFDAApprovalHistory.7September2020[2022-09-20].锛堝師濮嬪唴瀹瑰瓨妗ｄ簬2022-09-22锛?
- ^FassiadisN.Rivaroxaban,thefirstoral,directfactorXainhibitor.ExpertOpiniononPharmacotherapy.December2009,10(18):2945鈥?946.PMID聽19925048.S2CID聽23498967.doi:10.1517/14656560903413559.
- ^LowensternA,Al-KhatibSM,SharanL,ChatterjeeR,AllenLaPointeNM,ShahB,etal.InterventionsforPreventingThromboembolicEventsinPatientsWithAtrialFibrillation:ASystematicReview.AnnalsofInternalMedicine.December2018,169(11):774鈥?87..PMID聽30383133.doi:10.7326/M18-1523.
- ^G贸mez-OutesA,Terleira-Fern谩ndezAI,Calvo-RojasG,Su谩rez-GeaML,Vargas-Castrill贸nE.Dabigatran,Rivaroxaban,orApixabanversusWarfarininPatientswithNonvalvularAtrialFibrillation:ASystematicReviewandMeta-AnalysisofSubgroups.Thrombosis.2013,2013:640723..PMID聽24455237..
- ^BrownDG,WilkersonEC,LoveWE.Areviewoftraditionalandnoveloralanticoagulantandantiplatelettherapyfordermatologistsanddermatologicsurgeons.JournaloftheAmericanAcademyofDermatology.March2015,72(3):524鈥?4.PMID聽25486915.doi:10.1016/j.jaad.2014.10.027.
- ^Overview|Rivaroxabanforthetreatmentofdeepveinthrombosisandpreventionofrecurrentdeepveinthrombosisandpulmonaryembolism|Guidance|NICE.www.nice.org.uk.[January1,2020].锛堝師濮嬪唴瀹瑰瓨妗ｄ簬2020-05-13锛?
- ^SunkaraT,OforiE,ZarubinV,CaugheyME,GaduputiV,ReddyM.PerioperativeManagementofDirectOralAnticoagulants(DOACs):ASystemicReview.HealthServicesInsights.2016,9(Suppl1):25鈥?6..PMID聽28008269.doi:10.4137/HSI.S40701.
- ^MueckW,KubitzaD,BeckaM.Co-administrationofrivaroxabanwithdrugsthatshareitseliminationpathways:pharmacokineticeffectsinhealthysubjects.BritishJournalofClinicalPharmacology.September2013,76(3):455鈥?6..PMID聽23305158.doi:10.1111/bcp.12075.
- ^MedicationGuide鈥揦arelto(PDF).U.S.FoodandDrugAdministration.[September1,2014].锛堝師濮嬪唴瀹瑰瓨妗?PDF)浜?014-05-02锛?
- ^XareltoSideEffects.WebMD.[September1,2014].锛堝師濮嬪唴瀹瑰瓨妗ｄ簬2014-09-03锛?
- ^XareltoSideEffectsCenter.RxList.[September1,2014].锛堝師濮嬪唴瀹瑰瓨妗ｄ簬2014-09-03锛?
- ^寮曡瘉閿欒锛氭病鏈変负鍚嶄负
Brown20152鐨勫弬鑰冩枃鐚彁渚涘唴瀹?/li> - ^RaschiE,PoluzziE,KociA,SalvoF,ParienteA,BiselliM,etal.Liverinjurywithnoveloralanticoagulants:assessingpost-marketingreportsintheUSFoodandDrugAdministrationadverseeventreportingsystem.BritishJournalofClinicalPharmacology.August2015,80(2):285鈥?3..PMID聽25689417.doi:10.1111/bcp.12611.
- ^RussmannS,NiedrigDF,BudmigerM,SchmidtC,StiegerB,H眉rlimannS,Kullak-UblickGA.Rivaroxabanpostmarketingriskofliverinjury(PDF).JournalofHepatology.August2014,61(2):293鈥?00[2022-09-20].PMID聽24681117.doi:10.1016/j.jhep.2014.03.026.锛堝師濮嬪唴瀹瑰瓨妗?PDF)浜?018-12-11锛?
- ^SchroederC.ISMPRanksXareltoMostDangerousDrugintheUnitedStates.DrugNews.DrugNews.[August10,2016].锛堝師濮嬪唴瀹瑰瓨妗ｄ簬2016-08-11锛?
- ^SchroederC.PossibleAntidoteCouldHelpBloodThinnerPatientsInBleedingEmergencies.DrugNews.[August20,2015].锛堝師濮嬪唴瀹瑰瓨妗ｄ簬2015-05-10锛?
- ^MoY,YamFK.Recentadvancesinthedevelopmentofspecificantidotesfortarget-specificoralanticoagulants.Pharmacotherapy.February2015,35(2):198鈥?07.PMID聽25644580.S2CID聽22593448.doi:10.1002/phar.1532.
- ^AcceleratedApprovalforAndexXa(PDF).FDA.[August1,2018].锛堝師濮嬪唴瀹瑰瓨妗?PDF)浜?018-07-26锛?
- ^U.S.FDAApprovesPortolaPharmaceuticals'Andexxa庐,FirstandOnlyAntidotefortheReversalofFactorXaInhibitors.PortolaPharmaceuticalsInc.(GlobeNewswireNewsRoom).[August1,2018].锛堝師濮嬪唴瀹瑰瓨妗ｄ簬2021-04-10锛?
- ^RoehrigS,StraubA,PohlmannJ,LampeT,PernerstorferJ,SchlemmerKH,etal.Discoveryofthenovelantithromboticagent5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide(BAY59-7939):anoral,directfactorXainhibitor.JournalofMedicinalChemistry.September2005,48(19):5900鈥?.PMID聽16161994.doi:10.1021/jm050101d.
- ^AnsellJ.OutpatientOralAnticoagulantTherapy.ConsultativeHemostasisandThrombosisFourth.Elsevier.January2019:747鈥?77.ISBN978-0-323-46202-0.doi:10.1016/B978-0-323-46202-0.00037-6.
- ^BerkrotB.Newbloodthinner'antidote'tohelpdoctorsmovepastwarfarin.Reuters.December23,2015[2022-09-20].锛堝師濮嬪唴瀹瑰瓨妗ｄ簬2019-04-03锛?
- ^TurpieAG.Neworalanticoagulantsinatrialfibrillation.EuropeanHeartJournal.January2008,29(2):155鈥?5.PMID聽18096568..
- ^ErikssonBI,BorrisLC,DahlOE,HaasS,HuismanMV,KakkarAK,etal.Aonce-daily,oral,directFactorXainhibitor,rivaroxaban(BAY59-7939),forthromboprophylaxisaftertotalhipreplacement.Circulation.November2006,114(22):2374鈥?381.PMID聽17116766..
- ^寮曡瘉閿欒锛氭病鏈変负鍚嶄负
XareltoFDAlabel2鐨勫弬鑰冩枃鐚彁渚涘唴瀹?/li> - ^StampfussJ,KubitzaD,BeckaM,MueckW.Theeffectoffoodontheabsorptionandpharmacokineticsofrivaroxaban.InternationalJournalofClinicalPharmacologyandTherapeutics.July2013,51(7):549鈥?61.PMID聽23458226.doi:10.5414/CP201812.
- ^EuropeanMedicinesAgency.CHPAssessmentReportforXarelto(EMEA/543519/2008)(PDF).2008[June11,2009].
- ^SinghAK,NoronhaV,GuptaA,SinghD,SinghP,SinghA,SinghA.Rivaroxaban:Drugreview.CancerResStatTreat.2020,3:264鈥?69.doi:10.4103/CRST.CRST_122_19.
- ^BayercommentsonarticleinTheBritishMedicalJournal(BMJ)regardingXarelto(PDF).BayerAGCommunications,GovernmentRelations&CorporateBrand.September29,2016[2022-09-20].锛堝師濮嬪唴瀹瑰瓨妗?PDF)浜?017-01-31锛?
- ^Bayer'sXareltoApprovedinCanada(鏂伴椈绋?.Bayer.September16,2008[January31,2010].锛堝師濮嬪唴瀹瑰瓨妗ｄ簬2011-07-11锛?
- ^Bayer'sNovelAnticoagulantXareltonowalsoapprovedintheEU(鏂伴椈绋?.Bayer.February10,2008[January31,2010].锛堝師濮嬪唴瀹瑰瓨妗ｄ簬2008-10-22锛?
- ^FDAapprovesXareltotopreventstrokeinpeoplewithcommontypeofabnormalheartrhythm.USFoodandDrugAssociation.November4,2011[April27,2016].锛堝師濮嬪唴瀹瑰瓨妗ｄ簬2011-11-05锛?
- ^Bayer,Johnson&Johnsonsettlemorethan25,000lawsuitsoverbloodthinnerXareltofor$775million.washingtonpost.com.[April7,2019].锛堝師濮嬪唴瀹瑰瓨妗ｄ簬2019-03-26锛?
- ^ThomasK.DocumentClaimsDrugMakersDeceivedaTopMedicalJournal.TheNewYorkTimes.March1,2016[May3,2016].锛堝師濮嬪唴瀹瑰瓨妗ｄ簬2016-03-05锛?
- ^PatelV.Dukeclinicaltrialunderscrutinyindrugcase.TheChronicle.DukeStudentPublishingCompany.[2022-09-20].锛堝師濮嬪唴瀹瑰瓨妗ｄ簬2016-05-08锛?
- ^PatelMR,MahaffeyKW,GargJ,PanG,SingerDE,HackeW,etal.Rivaroxabanversuswarfarininnonvalvularatrialfibrillation.TheNewEnglandJournalofMedicine.September2011,365(10):883鈥?1..PMID聽21830957.doi:10.1056/NEJMoa1009638.
- ^MeetRobertM.Califf,M.D.,CommissionerofFoodandDrugs.U.S.FoodandDrugAdministration.U.S.FoodandDrugAdministration.[May3,2016].锛堝師濮嬪唴瀹瑰瓨妗ｄ簬2016-05-15锛?
- ^PatelMR,HellkampAS,FoxKA.Point-of-CareWarfarinMonitoringintheROCKETAFTrial(PDF).TheNewEnglandJournalofMedicine.February2016,374(8):785鈥?[2022-09-20].PMID聽26839968.doi:10.1056/NEJMc1515842..锛堝師濮嬪唴瀹瑰瓨妗?PDF)浜?018-07-22锛?
Brown20152鐨勫弬鑰冩枃鐚彁渚涘唴瀹?/li>XareltoFDAlabel2鐨勫弬鑰冩枃鐚彁渚涘唴瀹?/li>
